Here, increased differential gene expression of MSR1, BCL10, NOD1, NOD2, NLRP12, NLRC4, TP53 and EGFR gene expression in GBM indicates altered innate immune signaling and other core cell signaling pathways in glioma pathogenesis. The gene discussed is NLRC4; the disease is central nervous system cancer.